Accelrys Completes Merger with Symyx; Will Cut up to 15 Percent of Combined Workforce | GenomeWeb

Accelrys this week completed its all-stock merger with Symyx Technologies, forming a scientific informatics company with more than 1,350 customers and annual revenues of approximately $170 million.

The new firm will do business under the name of Accelrys and will trade on the Nasdaq stock exchange under the symbol ACCL.

In documents filed with the US Securities and Exchange Commission after the merger, Accelrys disclosed that it plans to lay off approximately 80 employees, or between 10 percent and 15 percent of new entity's combined workforce.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.